Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$17-$20 moving average.
Wonder if it will Squeeze Higher!?
Ma200 is a mile high Blue sky Up.
Stocks called out was GBTC under $150 and ran to $3500.
That was the biggest move I've seen in a long time.
***$8 Gap fill and $17-20 MA's ***
It was never pumped though. Barely any volume. For a low floaters they could’ve pumped it real hard and didn’t do anything
Market tells you what they think. This company (or their underwriters) will pump up their stock price just prior to PP announcement and then it crashes after the news. I would NEVER go near this stock. I have never owned it to follow it for some reason.
David.
Yup. I guess an RS to bring the price all the way up to $10 was to facilitate an offering. Either way, super low float and those 130k shares will likely convert very quickly. Might be a good bounce play coming from sub $5
No wonder CHFS dumped today!
CHF Solutions, Inc. Announces Pricing of $10.8 Million Underwritten Public Offering
EDEN PRAIRIE, Minn., March 08, 2019 (GLOBE NEWSWIRE) -- CHF Solutions, Inc. (NASDAQ:CHFS) today announced the pricing of an underwritten public offering of units for gross proceeds of approximately $10.8 million prior to deducting underwriting discounts and commissions and offering expenses payable by CHF Solutions.
The offering is comprised of (1) 146,607 Class A Units, priced at a public offering price of $5.25 per unit, with each unit consisting of one share of common stock, a Series 1 warrant to purchase one share of common stock at an exercise price of $5.25 per share that expires on the fifth anniversary of the date of issuance and a Series 2 warrant to purchase one share of common stock at an exercise price of $5.25 per share that expires on the earlier of the eighteen-month anniversary of the date of issuance and the 30th trading day following public announcement by CHF Solutions of receipt from the U.S. Food and Drug Administration (FDA) of clearance or approval of a modification to the product label for the Aquadex FlexFlow® system to include pediatric patients, and (2) 1,910,536 Class B Units, priced at a public offering price of $5.25 per unit, with each unit consisting of one share of Series G convertible preferred stock, convertible into one share of common stock, a Series 1 warrant to purchase one share of common stock with an exercise price of $5.25 per share and a Series 2 warrant to purchase one share of common stock with an exercise price of $5.25 per share.
The conversion price of the preferred stock issued in the transaction as well as the exercise price of the warrants are fixed and do not contain any variable pricing features or any price based anti-dilutive features. The preferred stock issued in this transaction includes a beneficial ownership blocker but has no dividend rights (except to the extent that dividends are also paid on the common stock) or liquidation preference, and, subject to limited exceptions, has no voting rights. The securities comprising the units are immediately separable and will be issued separately. The closing of the offering is expected to take place on or about March 12, 2019, subject to the satisfaction or waiver of customary closing conditions.
Ladenburg Thalmann & Co. Inc., a subsidiary of Ladenburg Thalmann Financial Services Inc. (NYSE American: LTS), is acting as sole book-running manager in connection with the offering.
A total of 146,607 shares of common stock, 1,910,536 shares of Series G convertible preferred stock, Series 1 warrants to purchase up to 2,057,143 shares of common stock and Series 2 warrants to purchase up to 2,057,143 shares of common stock will be issued in the offering. In addition, the Company has granted the underwriters a 45-day option to purchase up to 308,571 additional shares of common stock, additional Series 1 warrants to purchase up to 308,571 shares of common stock and/or additional Series 2 warrants to purchase up to 308,571 shares of common stock solely to cover over-allotments, if any, at the public offering price per share and per warrant, less the underwriting discounts and commissions.
The securities were offered pursuant to a registration statement on Form S-1 (File No. 333-229102), which was declared effective by the United States Securities and Exchange Commission (“SEC”) on March 7, 2019 and an additional registration statement filed pursuant to Rule 462(b) (File No. 333-230142), which became effective when filed.
This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor will there be any sales of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction. The offering is being made solely by means of a prospectus. A final prospectus relating to this offering will be filed by CHF Solutions with the SEC. When available, copies of the final prospectus can be obtained at the SEC’s website at www.sec.gov or from Ladenburg Thalmann & Co. Inc., Prospectus Department, 277 Park Avenue, 26th Floor, New York, New York 10172 or by email at prospectus@ladenburg.com.
About CHF Solutions
CHF Solutions, Inc. (Nasdaq:CHFS) is a medical device company focused on commercializing the Aquadex FlexFlow system for aquapheresis therapy. The Aquadex FlexFlow system is indicated for temporary (up to eight hours) ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and extended (longer than 8 hours) ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and require hospitalization. All treatments must be administered by a healthcare provider, under physician prescription, both of whom having received training in extracorporeal therapies. The company's mission is to predict, measure, and control patient fluid balance through science, collaboration, and innovative medical technology. CHF Solutions is a Delaware corporation headquartered in Minneapolis, Minnesota with wholly owned subsidiaries in Australia and Ireland. The company has been listed on the Nasdaq Capital Market since February 2012.
On watch. Nice pullback to sub $10. Could be worth a long position
I filled Fri my first order. 513,000 O/S, 5.5 mil cash, 0 debt.
CHF Solutions, Inc. Announces 80% Revenue Growth for its Fourth Quarter and Provides Company Update
EDEN PRAIRIE, Minn., Feb. 20, 2019 (GLOBE NEWSWIRE) -- CHF Solutions, Inc. (Nasdaq: CHFS) announced today its results for the fourth quarter and year ended December 31, 2018, which included the following highlights:
Revenue for the fourth quarter ended December 31, 2018 increased 80.4 percent compared to the same period in 2017. Revenue growth for the year 2018 was 40.7 percent compared to the year 2017.
Continued marketing focus into post-cardiovascular surgery and heart failure outpatient clinics.
Commenced discussions with the FDA to request a label modification to include pediatrics.
Continued international expansion with announcement of new distributor agreements in India and Brazil.
Announced the filing of two new patent applications to deepen the company’s intellectual property protection of its Aquadex Flexflow® system.
Ended the quarter with $5.5 million in cash and cash equivalents and no debt.
“Our fourth quarter and year-end performance reflects the significant work our team accomplished during 2018. We achieved impressive revenue growth and continued to make strides in our commercialization efforts,” said John Erb, chairman and CEO of CHF Solutions. “I look forward to executing on the additional market opportunities we have identified, which we believe will deliver additional growth in 2019 and beyond.”
The Company will host a conference call and webcast at 9:00 AM ET today to discuss its financial results and provide an update on the Company’s performance. To access the live webcast, please visit http://ir.chf-solutions.com/events. Alternatively, you may access the live conference call by dialing (877) 303-9826 (U.S.) or (224) 357-2194 (international) and using conference ID: 4589101. An audio archive of the webcast will be available following the call at http://ir.chf-solutions.com/events.
Low float 510k OS.
Low market cap $5.3mm.
Warrants at $29 and $50.
Let’s go ??
Carl Icahn took position today (Jan 3rd)
I'm curious as to what the R/S ratio will end up being.... Tick tock
Correction.... December 28th to be correct.
R/S incoming once approved on Dec 8th... Glad I held off the trigger!
VA CONTRACT..IN HOUSE MANUFCTG..BULLISH AF $CHFS
* * $CHFS Video Chart 07-25-18 * *
Link to Video - click here to watch the technical chart video
Out @ $1.85 for sizable loss, minimized today. Not a stock to trade when you don't have a off market hours trading account. Twice recently watched pre-market sizable jumps dwindle.
CHFS
CHFS...$1.83...Pre market on News...Chart linked from $1.50 alert...
https://www.otcmarkets.com/stock/CHFS/news/story?e&id=1134216
Department of Veterans Affairs Awards a $6.5 million Blanket Purchase Agreement to CHF Solutions to Supply Aquadex FlexFlow System for Outpatient Services in Tampa, Fla.
About time this turned.... more contracts to come!
CHFS...$1.63...Hit $1.90 Hod...Chart linked from $1.50 alert...Psar flipped to a Bullish Buy signal on Strong Volume as the Pincher starts to diverge...
CHFS...$1.68...looking to test the 200ma resistance again on the 30 minute chart...very possible $2. breakout if the pressure sticks...imo...we shall see...
CHFS...$1.66...Psar flipped to a bullish Buy signal...
CHFS...$1.70...Chart linked from $1.50 alert...
CHFS...$1.50...Oversold Pincher Chart...Macd ready to cross...Williams signaling a reversal as an Inverted Hammer forms on the bottom...Psar ready to flip to a bullish Buy position...Looking for possible entry...
Recent Form 4...
https://www.otcmarkets.com/filing/html?id=12851124&guid=V4voUFrm_AATlth
I did really well buying into the small Reverse Split as it ran to $25 Range...
100% agreement
What is the CEO's compensation annually, ash?
Management should be replaced asap.
I sold CHFS awhile back in one account for a break even. In the other one I sold shortly after the dilution and after it was brought to my attention that a large amount of warrants strike price was lowered by CHFS. It was a big mistake buying this stock and lesson learned for me. Bad management for sure.
What is the Number #1 reason you are still holding CHFS?
And why should a new investor consider buying CHFS now (if it is a different reason than your answer to the first question?)
Thanks in advance for your reply.
I have no idea. See no news and see no tweets suggestive of news. It has a high Beta suggesting high volatility so assuming it is just an early take down, but it should be recovering. Bought more @ $2.40.
Suppose some holders are just getting tired of the decline and selling.
Don't know the company well but have watched it a month or so. You know it?
CHFS
Vow....down by 10% today....does anyone k ow what’s going on?
Two days of low volume and down over-all market and the chart set-up is now gone.
CHFS
Today market is up by 200 points and still this pos is down. This incompetent management who can’t bring value to stockholders needs to be fired without golden parachute!
Don't know much about management, but was frustrating day to watch. No volume the 1st half of day, but when volume came was always someone selling. Don't believe there is a large short position here.
Not going to marry it as had an ask in all day.
Good luck with it.
CHFS
If market goes down this pos goes down. If market goes up this pos goes down. So no matter what markets does, this pos goes down. This is happening solely because of incompetent management who can’t bring value to stockholders. This non-performing mediocre-capacity below-average n highly compensated management needs to be fired without any golden parachute!
In @ $2.75. 1st time trading.
Seems to have solid financials (Cash, Book and Current/Quick ratios:
https://finviz.com/quote.ashx?t=CHFS&ty=c&ta=1&p=d
CHFS
Agree.keep holding because such a great company/ products must pays off at some point. Who knows maybe this company will be bought out or management will be forced to step out.
So now you agree that this great company having great products is having the worst performing management. For shareholders to get value out of this great company, this non-performing, mediocre-capacity, below-average, highly-compensated management needs to be fired or their salaries and bonuses should be cut completely until they return value to shareholders!
$chfs solid company, strong balance sheet ( completely Debt-free), commercial contracts boost (Q1), but failed Management ( unable to create shareholders Value).
More green again today.. turning around
CHFS
Yesterday CHFS management was interviewed on Fox Business and Bloomberg. When great company’s management talks their stock goes up because their management is also great! Whereas in CHFS case look what CHFS stock is doing today in spite of markets being up. This speaks volumes about this incompetent management. This incompetent management needs to be fired for CHFS shareholders to get value and CHFS stock to go up!
This interview today with CHFS should give them worldwide exposure which should be very beneficial. I may be joining you back in the near future with PIOE.
Both will do well, I’m in KTOV too, CHFS looks healthy for growth.
I sold my PIOE but may buy back again. I am in here pretty big and many warrants at 91 cents on KTOVW with fingers crossed. Wish I had some more cash to get the cheaper shares on CHFS.
Followers
|
65
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
1655
|
Created
|
07/06/12
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |